BNP Paribas Financial Markets Decreases Stake in Qiagen N.V. $QGEN

Key Points

• BNP Paribas Financial Markets reduced its stake in Qiagen N.V. by 17.1%, selling 258,120 shares, which leaves them with approximately 1,251,587 shares valued at $50.25 million.
• Several institutional investors, including Wellington Management Group and Deutsche Bank AG, increased their investments in Qiagen, with Deutsche Bank boosting its holdings by 57.5%.
• Qiagen reported a quarterly earnings per share (EPS) of $0.60, aligning with analyst expectations, and recorded a 7.7% increase in revenue year-over-year.

BNP Paribas Financial Markets trimmed its holdings in Qiagen N.V. (NYSE:QGEN - Free Report) by 17.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,251,587 shares of the company's stock after selling 258,120 shares during the quarter. BNP Paribas Financial Markets owned about 0.56% of Qiagen worth $50,251,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. SVB Wealth LLC purchased a new stake in Qiagen during the 1st quarter valued at about $31,000. ANTIPODES PARTNERS Ltd purchased a new stake in Qiagen during the 1st quarter valued at about $94,000. Tower Research Capital LLC TRC grew its position in Qiagen by 770.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after purchasing an additional 2,204 shares during the last quarter. GAMMA Investing LLC grew its position in Qiagen by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after purchasing an additional 1,425 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new stake in Qiagen during the 1st quarter valued at about $150,000. 70.00% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on QGEN. Bank of America raised their price target on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a report on Thursday, June 26th. UBS Group lifted their price objective on shares of Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Barclays began coverage on shares of Qiagen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price for the company. Cowen reaffirmed a "hold" rating on shares of Qiagen in a research note on Thursday, August 7th. Finally, Wall Street Zen lowered shares of Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Three analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $49.69.

Qiagen Stock Performance

Qiagen stock traded up $0.50 during mid-day trading on Friday, hitting $47.54. The company had a trading volume of 939,634 shares, compared to its average volume of 1,350,406. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. Qiagen N.V. has a 12-month low of $37.63 and a 12-month high of $51.88. The company's fifty day moving average is $48.65 and its 200-day moving average is $44.38. The company has a market capitalization of $10.57 billion, a price-to-earnings ratio of 28.08, a P/E/G ratio of 2.51 and a beta of 0.64.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting the consensus estimate of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The firm had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. During the same period in the prior year, the company earned $0.55 EPS. The firm's revenue was up 7.7% compared to the same quarter last year. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Equities research analysts predict that Qiagen N.V. will post 2.26 EPS for the current year.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.